Dying or Lying? For-Profit Hospices and End of Life Care

By Jonathan Gruber, David Howard, Jetson Leder-Luis and Theodore Caputi*

Jan 18, 2023

The Medicare hospice program is intended to provide palliative care to terminal patients, but patients who have long stays in hospice can be highly profitable, motivating concerns about overuse in the Alzheimer's and Dementia (ADRD) population. We use the rapid entry of for-profit hospices over twenty years to evaluate the effects of hospice on ADRD patient spending and mortality. We show that hospice actually saves money for these uncertainly eligible patients. We then show that caps on hospice earnings cause harmful distortions with relatively little savings, and that anti-fraud lawsuits deter admission among patients who may save money on the margin.

* Jonathan Gruber: MIT and NBER
David Howard: Emory School of Public Health
Jetson Leder-Luis: Boston University and NBER. Corresponding author. Email: jetson@bu.edu
Theodore Caputi: MIT

We are very grateful for the feedback from Amy Finkelstein, Ashvin Gandhi, James Poterba, Maggie Shi, and Andrei Shleifer. We thank participants of the National Tax Association health group meeting, the ASHEcon conference, the Boston University Applied Microeconomics Seminar, and the MIT Public Finance Lunch. Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG012810. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1. Introduction

The intensive and costly treatment of patients near the end of life is a persistent source of criticism of the US healthcare system (Porter, 2012). Policymakers have responded by authorizing payment for alternatives to traditional physician and inpatient care, such as hospice care. First introduced in 1983, the hospice benefit allows patients with a life expectancy of less than 6 months to receive palliative care at home in return for agreeing to forgo curative therapy. The hope was that hospice care would improve the experience of dying while reducing Medicare spending (Davis, 1988). Since its inception, hospice use has grown enormously, accounting for more than $20 billion in federal spending by 2019, amounting to $13,000 per enrollee on average or $500 for every Medicare beneficiary in the U.S.

While hospice is an attractive option in theory, there is little evidence on its impact on health care costs. There are competing factors: while hospice patients may forgo other expensive forms of care, hospice providers are paid hundreds of dollars per patient per day for their services. The costs incurred by hospice patients for hospice care may more than offset savings from reductions in spending on curative care. In addition, eligibility standards are open to interpretation: hospices are required to certify that their patients have a life expectancy of less than 6 months to be eligible, but predicting this outcome is challenging. Einav *et al* (2018) show that just 5% of end-of-life spending comes from individuals with a greater than 50% predicted mortality. Moreover, the patients who incur the highest end-of-life costs may be those with the lowest ex ante risk of death and thus may be ineligible for hospice.

Hospices face an incentive to disregard Medicare's hospice eligibility rules and admit patients who are not within 6 months of death. Hospice care, like most Medicare services, is provided by private providers who are reimbursed by Medicare, and many of these providers operate as for-profit firms. Hospices' costs of providing care are highest in the period immediately following admission and the period immediately preceding death and lower in the intervening period (Huskamp, Newhouse, Norcini, & Keating, 2008; MedPAC, 2006). Yet hospices are paid a fixed daily rate; consequently, patients with longer lengths of stay are more profitable than short-stay patients. Predicting life expectancy is an inexact science, and physicians employed by hospices are often responsible for determining eligibility.

The rapid growth of the for-profit sector in hospice care has potentially exacerbated the mismatch between hospice's financial incentives and Medicare's eligibility guidelines. From

2000 to 2019, the number of for-profit hospice firms quintupled while the number of non-profit firms was substantively unchanged. Concurrent with this growth has been an enormous expansion of the hospice program, which grew from roughly $2.5 billion in 1999 to over $20 billion in Medicare spending in 2019 (MedPAC, 2004) (MedPAC, 2021). Recent press coverage has highlighted pernicious behavior by for-profit hospices, such as actively seeking to enroll non-terminally ill beneficiaries (Kofman, 2022). Since 1999, dozens of the largest for-profit hospices have collectively paid hundreds of millions to the Department of Justice to settle allegations that they admitted ineligible patients. Yet, the ability of the government to enforce eligibility standards is unclear: in one high-profile case, the court sided with the hospice on the grounds that claims about patients' life expectancy cannot be "objectively false" given the inherent uncertainty in predicting survival.[1]

Accusations of unnecessary admissions have often focused on patients with Alzheimer's Disease and Related Dementias (ADRD), who tend to have long hospice lengths-of-stay and a particularly uncertain prognosis. For example, the hospice firm Evercare paid $18 million to settle allegations that it admitted ineligible patients. Whistleblowers alleged that the firm sought out patients with Alzheimer's disease and dementia because "once certified as 'terminally ill', [d]efendants would be able to keep these types of patients on census for lengthy periods of time."[2] The entry of for-profit hospices over the past several decades has coincided with a large increase in the number of patients admitted with a diagnosis of ADRD. In 1999, about 4.4% of ADRD patient-years included a hospice stay, and by 2019 that number had risen to nearly 14.7%. ADRD patients now make up 38% of hospice episodes. They account for 48% of hospice episodes that last over six months and 51% of hospice episodes over a year.

In this paper, we study the effects of hospice usage on patient outcomes and Medicare spending in the ADRD population and evaluate the impact of policies designed to curtail overuse

[1] See: United States vs Aseracare, Inc. The Eleventh Circuit Court affirmed a judgement by the Northern District of Alabama that: "contradiction based on clinical judgment or opinion alone cannot constitute falsity under the FCA as a matter of law." Moreover, they wrote ""a clinical judgment of terminal illness warranting hospice benefits under Medicare cannot be deemed false, for purposes of the False Claims Act, when there is only a reasonable disagreement between medical experts as to the accuracy of that conclusion, with no other evidence to prove the falsity of the assessment." For legal analysis, see (Hogan Lovells FCA Alert, 2019).

[2] See: United States ex rel. Fowler v. Evercare Hospice, Inc., case 11-cv-000642, District of Colorado. Quote is from the whistleblower, as relayed by Judge Phillip A. Brimmer in a motion dated September 21, 2015. Available online at: https://www.casemine.com/judgement/us/5914ad9cadd7b04934743575

of the hospice benefit. We begin by providing the first causal estimates of the impact of hospice enrollment for the marginal patient. To identify this estimate, we exploit the rapid entry of for-profit hospices, which exposes Medicare beneficiaries to varying levels of hospice access over time and by location. Specifically, we use variation in a standard distance-based instrument with locality fixed effects to identify the effects of hospice care from changes in for-profit hospice access among people living in the same zip code but diagnosed at different times.

We find striking evidence that, despite concerns about fraudulent behavior, hospice for the marginal ADRD patient saves money, mostly due to large reductions in the use of skilled nursing facilities and home health care. On average, we estimate a savings of $45,300 to Medicare for each marginally admitted ADRD hospice patient. Our results suggest that, on the margin, expanding hospice eligibility would reduce costs for long-term care, even if it meant bringing in patients who might live longer than 6 months. These results may underestimate the cost savings of hospice care, as we only estimate savings to the Medicare program and do not include savings to the Medicaid and Social Security programs. We also find that the marginal hospice patient with ADRD is 17% more likely to die in five years if she uses hospice. The welfare implications of mortality increases are unclear, however, given that hospice patients agree to forgo life-saving care.

We focus on the impact of hospice on outcomes among patients with Alzheimer's Disease and Related Dementias (ADRD) for several reasons. This population is of direct relevance to policy debates about curtailing hospice overuse. Unlike patients with late-stage cancer, for example, ADRD patients have an uncertain prognosis and, when admitted to hospice, long average length of stays. Moreover, legal disputes about the appropriateness of hospice, or whether admissions were fraudulent, have often revolved around the appropriateness of hospice specifically for ADRD patients. There is also a practical reason for focusing on ADRD patients: ADRD patients form a cohort that has a non-negligible risk of hospice entry and also includes patients for whom the benefit of hospice is questionable. Alternative approaches to constructing a cohort - for example, identifying patients with a high risk of death - would satisfy one of these criteria but not the other.

The finding that for-profit hospice exposure saves money for ADRD patients motivates a study of the policy mechanisms that combat hospice use by that population. The government uses two policy levers to limit hospice overuse: a revenue cap and antifraud litigation. As a

complement to our main analysis, we directly evaluate the impact of these policies on costs and outcomes.

The aggregate cap on hospice revenues is used to limit long stays. The cap equals a fixed dollar amount multiplied by the number of patients admitted in a given fiscal year, computed for each hospice. Hospices must refund any revenues in excess of this amount, thereby counteracting hospices' incentives to admit long-stay patients. Hospices face a cliff in their revenue if patients stay too long, but the cap binds *in aggregate* for the firm, not at the patient level.

Compared to non-profit hospices, for-profit hospices have a considerably longer average duration of stay and consequently face higher cap pressure. We find that when facing pressure from the cap, hospices change how they treat patients. Patients in hospices facing cap pressure are more likely to be discharged from hospice alive, experience higher mortality rates, and are less likely to receive intensive hospice care. The cap also lowers patient-level spending, but only by roughly $2,300 over 12 months.

Second, the government seeks penalties from hospices suspected of over-admitting patients under the False Claims Act, a federal anti-fraud statute. Using new data from a Freedom of Information Act Request, we examine the effect of False Claims Act litigation on firm behavior with a difference-in-difference design. We find that litigated firms admit fewer long-staying patients and fewer ADRD patients. These firms substitute toward other patients who also save the government money, including cancer patients. However, we argue that this substitution, while useful in the short term, limits the long-term benefit of expanding hospice use to a broader population. Because marginal patients save money by going to hospice, federal litigation actually discourages hospices from admitting cost-saving patients. Hospice use is an unusual case where federal anti-fraud initiatives increase costs, because the marginal hospice admittee saves money.

Despite the widespread use of the hospice benefit and the open question of its effectiveness, there is remarkably little work on the topic. Prior studies of the effects of hospice care restrict attention to samples of decedents, thereby excluding the marginal or (potentially) fraudulently admitted patient (Kelley, Deb, Du, Aldrige Carlson, & Morrison, 2013). Some decedents studies compare hospice patients to non-hospice-goers, failing to address selection on unobservables (Aldridge, Moreno, & McKendrick, 2022). Patients admitted to hospice may be more or less healthy than those who are not, particularly in light of allegations of fraudulent or

inappropriate admissions decisions by for profit firms. Section 2.2 reviews the literature specific to hospice care.

Our work is also related to a literature on health care fraud and the effect of for-profit care on patient health. O'Malley *et al*. (2021) discuss fraud in Medicare home health care provision, documenting and measuring a rise in fraudulent overprovision of care by profit-maximizing firms. Leder-Luis (2019) reports that hospice is one of the large categories of False Claims Act lawsuits, and Howard (2020) discusses the legal issues surrounding medical necessity and fraud in hospice care, but neither measure the effects of hospice use or hospice fraud. In the context of for-profit care, Gupta *et al* (2021) and Gandhi *et al* (2022) study the implications of private-equity ownership of nursing homes for patient care, They reach conflicting conclusions about the welfare consequences of ownership. Gonda & Song (2019) consider the role of private equity in health care delivery and document the rise of private equity in health care. A 2021 MedPAC Report (MedPAC, 2021) consider the implications of private equity in health care and discusses the tradeoff between increased productive efficiency versus reductions in the quality of care.

This paper proceeds as follows. Section 2 discusses the institutional context of hospice and anti-fraud litigation against hospices and reviews the existing literature on hospice care. Section 3 presents our data, and section 4 describes the instrumental variables design and its results. Sections 5 addresses the hospice cap, our model and empirics, and its policy implications. Section 6 discusses hospice litigation and presents empirical evidence on the effect of hospice fraud lawsuits. Section 7 discusses our overall results, and Section 8 concludes.

2. Background: The Medicare Hospice Program

2.1 Hospice Program Overview

Terminally ill Medicare beneficiaries with a life expectancy of less than 6 months are eligible for hospice care. While hospice patients retain Medicare coverage for other conditions, such as injuries, they cannot receive curative treatment for the condition under which they are admitted to hospice. Hospices are responsible for ensuring the comfort of dying patients. They provide counseling, nursing visits, help with activities of daily living (*e.g*, bathing), chaplaincy, and pain management, which may entail the administration of opioids. Hospice is generally

provided at patients' place of residence, which may either be their home or a long-term care facility.

There are four levels of hospice care, each of which is reimbursed at a different rate. Routine Home Care accounts for over 98% of hospice care days. (National Hospice and Palliative Care Organization, 2020). Routine care is paid at a fixed daily rate that varies regionally. The daily payment rate for routine-home care in 2020 was $199.25 for days 1-60 and $157.49 for days ≥61; before 2015, the daily rate was constant. Payment is not adjusted for patient diagnosis. Hospices also have the ability to provide inpatient and respite care in rare circumstances of acute patient need.

Hospice payments and costs differ in their structure. While hospices face a near-constant daily payment rate, their costs are non-linear: the costs of hospice are highest at enrollment, when hospices incur the upfront costs of patient acquisition and enrollment, and at the end of life, when the patient needs the greatest care. Hospices earn the largest profits on patients with long lengths of stay. To combat the incentive to admit long-stay patients, Medicare has imposed an aggregate cap on hospice payments per firm. The formula for the cap takes an annual constant and multiplies it by the number of new patients the hospice admits in a given year. The constant is adjusted annually (but not regionally), and in 2019 it was $29,205. All revenue over this cap amount must be returned, producing a cliff in reimbursement. The cap applies at the firm level, not at the patient level. For example, if a hospice had two patients who incurred spending of $35,000 and $20,000 (for an average of $27,500), the hospice would fall below the cap. We empirically analyze the effects of the cap in Section 5.

Since 1996, there have been dozens of False Claims Act anti-fraud lawsuits filed against for-profit hospice firms for admitting patients who were not terminal or recertifying non-terminal patients. Many of the patients in question had Alzheimer's or dementia. The False Claims Act allows whistleblowers to file lawsuits against firms that defraud the federal government. Whistleblowers, who were often hospice employees, alleged that management pressured clinical staff to meet admissions targets and that hospice physicians certified patients as eligible without examining them.

Use of the False Claims Act to target hospices for admitting ineligible patients is controversial. Hospices have argued that their physicians' assessments of patient life expectancy, are inherently subjective and thus cannot be considered "false" under the Act. Federal appellate

circuit courts have disagreed on the matter, and litigants have asked the Supreme Court to weigh in. Our study provides evidence on the value of the application of the False Claims Act to hospices' admission decisions.

2.2 Related Literature

A large literature, primarily in public health, has examined various aspects of the use and expansion of hospice, although our paper is the first to examine its causal impact on patients, as well as to identify the effect of policies designed to limit hospice use.

Early supporters hoped to demonstrate that hospice is the rare instance of a medical innovation that improves patient welfare while simultaneously reducing costs (Krant, 1978). The early 1980s National Hospice Study sought to evaluate the impact of the nascent hospice movement by comparing spending and quality-of-life between terminal cancer patients treated in hospice and patients treated in conventional settings. The study found that hospice care reduced Medicare spending, but savings were concentrated in the last month of life (Greer, et al., 1986). More recently, studies have compared costs and other outcomes between decedents treated in hospice and matched non-hospice decedents (Harrison K. L., Cenzer, Ankuda, Hunt, & Aldridge, 2022; Kelley, Deb, Du, Aldrige Carlson, & Morrison, 2013; Leibowitz, Tan, & Gildner, 2020; Taylor Jr, Ostermann, Van Houtven, Tulsky, & Steinhauser, 2007). Estimates based on a fixed time period (e.g., the last year of life) tend to find that costs are similar, while those that analyze costs from the date of hospice enrollment onward tend to find substantial savings (Hogan & Neuman, 2015).

These studies exclude patients discharged alive from hospice and may be biased if patients who select into hospice have unobserved preferences for less intensive treatment. In addition, they do not address the impact of hospice care on the "marginal" patient, i.e., the types of patients for whom use of hospice is affected by antifraud enforcement and related policies because of their uncertain eligibility. To address selection, Hogan & Neuman (2015) use a long panel to estimate end-of-life costs among decedents as a function of market-level hospice penetration with region fixed-effects. They find that end-of-life costs increased more rapidly in markets that experienced more rapid growth in hospice enrollment, and that the effect was concentrated among non-cancer patients. More recently, researchers have investigated whether the benefits associated with increased hospice enrollment, particularly among non-cancer

patients, justify potentially increased spending. Harrison et al. (2022) found that hospice improved quality of care among dementia patients in their last month of life, which suggests that increased hospice enrollment improves patient well-being, regardless of spending effects.

A handful of papers in the industrial organization literature have modeled hospice entry and competition, but do not estimate the effects of hospice on spending or patient welfare. Chung and Sorensen ((2018)) build a model of market expansion among for-profit hospices and discuss the impacts on hospice use among cancer and dementia patients. Ho (1991) studied the role of local wage variation and firm profit status in the expansion of Medicare hospice benefit. Alam (2022) models the role of quality in patients' hospice choice.

The rapid entry of for-profit hospices and, more recently, acquisitions of hospices by other providers (e.g., home health agencies and nursing homes) (Gozalo, Mlotzke, Mor, Miller, & Teno, 2015; Stevenson, Sinclair, Zhang, Meneades, & Huskamp, 2020; Fowler, Grabowski, Gambrel, Huskamp, & Stevenson, 2017) and private equity firms (Braun, Stevenson, & Unruh, 2021) has spurred interest in the impact of hospice ownership on firm behavior. For-profit hospices admit more patients with a primary diagnosis of dementia, have longer average lengths of stay (Dalton & Bradford, 2019; Lindrooth & Weisbrod, 2007; Wachterman, Marcantonio, & Davis, 2011), and receive more referrals from nursing homes (Gandhi S. O., 2012). Differences in behavior are generally attributed to differences in the weight for-profit and non-profit hospices assign to patient welfare but may also arise from non-profit hospices' dependence on charitable donations. If revenue from donations depends on the number of patients served rather than the duration of service, non-profit hospices will face a stronger incentive to admit short-stay patients (Dalton & Bradford, 2019). Hospices can influence enrollment by cultivating referral relationships with other providers (e.g., case managers at hospitals) and by setting admission standards (for example, will the hospice accept patients receiving transfusions). For-profit hospices are more likely to impose restrictions on the patients they will accept (Aldridge Carlson, Barry, Cherlin, McCorkle, & Bradley, 2012).

Seeking to reduce incentives to admit long-stay patients, Congress enacted the Improving Medicare Post-Acute Care Transformation (IMPACT) Act which, among other provisions, subjected hospices with a high proportion of stays over 180 days to audits. In 2016, CMS increased the routine home care per diem payment for the first 60 days and last 7 days (for decedents) of an episode and lowered the payment for the intervening period. A time-series study

(Gianattasio, Ali, Lupu, Prather, & Power, 2022) found that after 2014, the proportion of patients admitted with an ADRD diagnosis initially declined but then increased, suggesting that hospices may have initially overestimated the stringency or intensity of audits. The shift away from uniform per diem payments had only a small effect on admission patterns.

As a result of the cap on their payments, discussed further in Section 5, hospices' incentives to admit and discharge patients may vary throughout the year (Ata, Killaly, Olsen, & Parker, 2012). For example, if patients admitted late in the prior cap year or early in the cap year end up staying longer than expected, the hospice will face a greater risk of exceeding the cap at the end of the year. As the hospice approaches the end of the cap year, it should admit fewer patients with long expected lengths of stays and discharge more patients. Dolin *et al.* (2018) find that hospices with longer lengths of stay tend to have higher live discharge rates, and Plotzke *et al* (2015) find that live discharge rates increase throughout the cap year, especially in hospices that exceed the cap.

3. Data and Descriptive Statistics

3.1 Data

We use 100% samples of Medicare Fee-for-Service claims data from 1999 through 2019,[3] including hospice claims, beneficiary enrollment files, chronic conditions indicators, hospitalization claims, and cost and use files. The hospice claims data allow us to identify patient-level hospice usage, providers, and payments. The Medicare beneficiary summary files include patients' zip codes and death dates, and the Chronic Conditions Warehouse files identify patients diagnosed with Alzheimer's Disease and Related Dementias (ADRD). We use the Cost and Use files to identify spending in different categories of care, such as inpatient, outpatient, and SNF care. We supplement information on the profit status and zip code of providers from the Provider of Service Files.

To better understand the nature of hospice litigation, we use data from the Department of Justice on fraud cases. We conducted a Freedom of Information Act (FOIA) request to identify all hospices subject to False Claims Act litigation. The Department of Justice identified 163 lawsuits against hospice companies and chains. We pair the FOIA data with substantive information from Department of Justice press releases and the Public Access to Court Electronic Records (PACER) system. We further combine our FOIA request, which contains defendant firm's names, with data from the NPI database to identify which providers in the Medicare data were subject to litigation. We supplement our understanding through numerous interviews with Department of Justice attorneys who litigated hospice fraud cases.

3.2 Descriptive Statistics on Hospice Use

We begin by documenting trends in the hospice industry that highlight concerns about overuse. Panel A of Figure 1 shows trends in the number of for-profit and not-for-profit hospices. Between 1999 and 2019, the number of for-profit hospice firms quintupled, from 615 firms to more than 3,252. Panel B shows the use of hospice care by ADRD patients. In 1999, 4.4% of ADRD patient-years included a hospice claim. By 2019, that number more than tripled

[3] As is standard in the health economics literature, we cannot observe patients who enroll in Medicare Advantage (Part C).

to 14.7%. Appendix Figure A1 shows trends in the geographic density of hospices between 2000 and 2014. The growth in hospice density was concentrated in the American South and Midwest.

As for-profit hospices have proliferated, the share of hospice patients that die within 6 months of admission has fallen, especially among for-profit firms. The number of for-profit hospice episodes for which the patients died within six months declined from 82.9% in 2000 to 73.5% in 2018. While it is to be expected that some patients do not die within 6 months because death is hard to predict, more than one-quarter of for-profit hospice patients may have been, *ex-post*, inappropriate for hospice care.

4. The Effects of Hospice Use on Patient Spending and Outcomes

4.1 Empirical Design

The goal of our empirical analysis is to understand the effect of hospice usage on patient spending and health outcomes. Because the patients that attend hospice may be selected along unobservable characteristics, we cannot compare those who attend to those who do not. Previous studies of hospice have started with the cohort of patients who died, and then matched hospice and non-hospice patients based on observable characteristics to estimate the effect of hospice usage (Aldridge, Moreno, & McKendrick, 2022). However, because death is only one potential outcome of hospice – particularly when the patient may be marginally eligible and not acutely terminally ill – a sample of decedents is heavily selected on outcomes.

Our strategy for estimating the effects of hospice relies on variation in patients' exposure to for-profit hospices based on where they live and the timing of their diagnosis among the sample of patients ever diagnosed with Alzheimer's Disease and Related Dementias (ADRD). We used the chronic conditions warehouse file to identify patients with ADRD and their comorbid conditions. We obtained patients' zip code and demographic characteristics from the enrollment file. We focus on the ADRD population because these are the "marginal" patients of most interest to policy makers and relevant to anti-fraud enforcement. Moreover, within this population, hospice use is sufficiently frequent that we can use an intent-to-treat design to address selection in who does and does not go to hospice.

Hospice use may change the length of time a patient spends in our sample, for example if hospice use impacts death. Therefore, we construct a cohort-based study where for each patient,

we consider the patient's health and spending outcomes in a fixed window of time following ADRD diagnosis. The choice of a time window has trade-offs: using a longer window allows us to examine longer-term outcomes, but longer windows also force us to restrict our sample to patients for whom we have more years of data. Because there is no clear correct answer for the window to use, we consider a window following diagnosis of [t, $t+5$] years, as the majority of patients are deceased five years after diagnosis. We also use a shorter window, [t, t+2], as a robustness check. The [t, t+5] window leads to a sample of patients who were first flagged as having Alzheimer's or dementia between 2000 and 2014.

Table 1 shows descriptive statistics for our main sample of ADRD patients. Our cohort consists of about 10.8 million patients. The mean age at diagnosis is 81. Sixty two percent of patients are female, 86% are white, and the mean distance to for-profit hospice is 18 miles. The patient population is relatively sickly: 59% have hypertension and 27% have diabetes at baseline. Seventy percent of patients die within 5 years.

We use a distance-based instrumental variables strategy to address selection into hospice. In particular, we instrument hospice use with the distance to the nearest for-profit hospice provider in a model that includes zip code fixed effects. The effect of hospice is therefore solely identified based on the entry and exit of for-profit providers, changing exposure at a zip code level. This design compares individuals in the same zip code before and after a hospice enters or exits. In contrast, estimates that rely solely on cross-sectional variation in patients' exposure to hospice could be biased by unobserved differences between patients who live near to or far from for-profit hospices.

Importantly, we rule out endogenous patient mobility after diagnosis by using each individual's zip code in the year before they first have an ADRD diagnosis flag, so that our estimates are identified only by hospice entry/exit and not by patient movement. That is, our identification comes from patients who live in the same zip code and who are diagnosed with ADRD in different years, where there is entry or exit of a hospice between patients' diagnosis dates. We also control for diagnosis cohort fixed effects, to account for general trends in both hospice entry and patient outcomes. Appendix A presents more details about the distance calculation. To address potential concerns about endogenous hospice location, below we show balanced trends before hospice entry.

We use two-stage least squares estimates to implement the instrumental variables design. For the first stage, we estimate the effect of exposure to for-profit hospice on hospice use:

$$Hospice_i = a_0 + \beta D_i + z_i + T_i + \delta X_i + e_i, \qquad (1)$$

where D_i is the patient's baseline distance to a for-profit hospice; z_i is a zip-code fixed effect; T_i is the diagnosis cohort fixed effect; and X_i is a matrix of patient characteristics including age at diagnosis, sex, race, and indicators of other chronic conditions at baseline. $Hospice_i$ is an indicator that equals 1 if the patient goes to hospice within 5 years. We also present estimates of the impact of distance on measures of hospice use that capture both intensive and extensive margin effects: length of stay and hospice spending (both are 0 for hospice non-users).

We then estimate the effect of hospice use on 5-year patient spending and mortality. We estimate:

$$Y_i = a_1 + \gamma \widehat{Hospice}_\imath + z_i + T_i + \delta X_i + e_i. \qquad (2)$$

where Y_i is spending on different categories of care or indicators for death within varying periods after diagnosis.

This design estimates the Local Average Treatment Effect for a population of compliers, for whom our instrument, exposure to for-profit hospice, increases the probability of hospice uptake. Importantly, our first stage dependent variable is *any* hospice use, to account for the fact that for-profit entry may impact the availability of non-profit hospices as well. In our results below, we further explore substitution between nonprofit and for-profit hospice as a function of entry by for-profit hospices.

4.2 Results

Table 2 presents the first-stage estimates of the coefficient β from Equation (1). Distance is scaled so that the coefficient represents the marginal effect of a 10-mile change to the nearest for-profit hospice. Being 10 miles closer to a for-profit hospice increases extensive margin use by 0.6 percentage points from a baseline of 33%, and length of stay (coded 0 for non-goers) is increased by 0.69 days on a baseline of 32 days. For each 10 miles a patient is closer to

a for-profit hospice, hospice spending increases by $77 on a baseline of $4,847. These estimates, while small, apply to the whole ever-ADRD population of 10.8 million individuals and are very precise, with $p < 0.001$ for each estimate and an F-statistic of 343 for the extensive margin model.

Figure 2 presents results from an analysis that treats the first stage as an event study (see Appendix B for details). Here, we consider zip codes that are treated discretely, which go from having no for-profit hospice within 50 miles to having a for-profit hospice within 10 miles. We plot the coefficients of first-stage extensive margin hospice usage among ADRD patients by year relative to hospice entry. There is no evidence of pre-trends, and the entry of a hospice is associated with about a 1 percentage point increase in hospice usage in subsequent years. Importantly, the first stage estimates we use in our two stage least squares design exploit the full range of changes in distance to a for-profit hospice at a zip code level, while this figure restricts attention to large discrete changes.

Appendix Figure A2 repeats the first stage event study analysis of Figure 2, taking into account recent critiques of two-way fixed effects estimators. We implement the Sun and Abraham's (2021) two-way-fixed effect corrected estimator. Our results are robust to this alternative estimator and show the same increases in hospice usage at the time of hospice entry.

Table 3 presents OLS and two-stage-least-squares estimates of the effect of hospice on a patient's spending within 5 years of diagnosis, γ from Equation (2). OLS estimates suggest that use of hospice increases spending, but these are biased positively by the sicker population that enrolls in hospice.

The two-stage-least-squares estimates can be interpreted as the effect on the complier population, for whom exposure to for-profit hospice leads to hospice admissions. For-profit hospice exposure increases spending on for-profit hospices by about $22,000. At the same time there is a shift away from spending on non-profit hospices of about $8,500. The net effect is a $13,500 increase in hospice spending. That is, new openings of for-profit hospices shift patients away from non-profit hospices as well as increasing overall hospice use.

However, hospice usage substantially decreases spending on two other expensive forms of care: skilled nursing and home health care. Among compliers, hospice enrollment causes a reduction in skilled nursing care spending of about $22,500 from a baseline mean of $12,700; similarly, hospice enrollment reduces home health expenditures by about $13,000 from a

population mean of about $5,600. The large reductions indicate that hospice use reduces spending on SNF and home health among a relatively expensive set of patients.

Hospice care causes a substitution away from inpatient treatment and toward outpatient treatment. We estimate that hospice use reduces 5-year spending on inpatient care by $9,400 from a base of $30,800. In contrast, hospice enrollment increases spending on hospital outpatient care by about $5,900 from a mean of $6,700. While hospice patients forfeit curative treatment for their terminal condition, they are still eligible to receive hospital outpatient care for other conditions. Hospice patients are also closely monitored by the hospice staff, who may refer patients for physician and hospital outpatient care for conductions unrelated to their terminal diagnosis.

Finally, hospice substantially decreases expenditures on Part D pharmaceuticals; spending decreases by $10,300 over 5 years from a baseline mean of $5,600. While there are no direct pharmaceutical therapies for ADRD covered by Medicare, these hospice patients are less likely to receive other forms of expensive drugs toward their end of life.

Considering the increased spending on hospice and hospital outpatient services and the decrease in spending on home health, skilled nursing facilities, and Part D drugs, hospice reduces 5-year spending among ADRD patients by $45,300 on net, or 56% from a base of $80,900.

To validate our finding that hospice patients receive less skilled nursing and home health care, we conduct a supplementary analysis to examine the discharge destination of ADRD patients following hospitalization. Skilled nursing care is used to provide post-acute care following hospitalization and often home health care is as well. Using the universe of hospitalizations of ADRD patients discharged from 2000 to 2018, we regress the share of patients discharged into different types of care on an indicator for whether patients were concurrently in hospice. Discharge categories include skilled nursing or home health or discharged home without care, versus discharged into hospice care or died in the hospital. Appendix Table A1 presents these results. Consistent with our IV findings, ADRD patients hospitalized with concurrent hospice visits are 9 percentage points less likely to be discharged to home health from a baseline of 12 percentage points and are 4 percentage points less likely to be transferred to another medical facility from a baseline mean of 57%. These patients are substantially less likely to be discharged home without further care; a reduction of 12 percentage points from a baseline of 23%. Conversely, these patients are 24 percentage points more likely

to be discharged into hospice from a baseline mean of 1%. These results are consistent with our early finding that hospice reduces the use of skilled nursing and home health care. Patients in hospice are also more likely to die in the hospital, reflecting differences in health status between hospice and non-hospice patients. The result also shows that even hospice patients use inpatient care to some degree at the end of life.

Table 4 presents the two-stage-least-squares and reduced-form estimates of the effect of hospice on mortality within 5 years of diagnosis. For this analysis, we use mortality in periods after the patient's exact date of ADRD diagnosis. Hospice enrollment increases 1-year-post diagnosis mortality by 14 percentage points from a baseline of 26% and 5-year post-diagnosis mortality by 16.8 percentage points from a baseline of 66.5%. We also find evidence of increased 90-day mortality: up 9.1 percentage points from a baseline of 12.7%. The increase may be due to ADRD patients forgoing urgent life-prolonging care. These estimates are all statistically significant at the 1% level, and the first-stage F-statistic is 343.

4.3 Robustness

In this section we demonstrate the robustness of our estimates to different specifications. We selected the window [t, t+5] after ADRD diagnosis in our main specification so that we had a sufficiently long time period to observe the spending and mortality effects of hospice. Appendix Table A2 presents parallel estimates using the window [t,t+2] after diagnosis. The sample includes patients diagnosed with ADRD from 2000 to 2017. The results are quite similar: hospice saves $33,000 over this period, driven by reductions in skilled nursing, home health and Part D, which offset increases in hospice spending. Similar to our main result, hospice usage in the ADRD population increases 0-2-year post-diagnosis mortality by 17.3 percentage points.

Our main specification uses patients' zip code to compute the distance to hospice in the year before they first have an ADRD flag in our data. To ensure the use of pre-diagnosis distance is not a source of measurement error, particularly given that patients may move, we repeat our main specification among non-movers. Appendix Table A3 presents results on the non-mover sample. Results are robust to this specification check.

Finally, we present specification checks to test the validity of our instrument (the distance to a for-profit hospice with zip fixed effects). Appendix Table A4 shows the covariate balance across patients above and below the median distance. Means are quite similar along most

dimensions, although patients who live nearer to for-profit hospices are somewhat more likely to be black and less likely to be white. They also spend more money on healthcare on average (while our IV estimates suggest that hospice reduces spending on the margin).

4.5 Discussion

Our results provide the first causal estimates of the impact of the $20 billion hospice program on total health care costs for marginal enrollees. Our results suggest that enrollment in hospice on the margin significantly reduces Medicare costs.

At the same time, we find that hospice expansion is associated with increased mortality. When patients enter hospice, they or their caregivers must sign a form indicating they understand that they will receive palliative care and not curative care. If effect, they are agreeing to accept a higher risk of death in return for gaining access to hospice care. In that case, it is not obvious that increased mortality due to hospice enrollment by the marginal patient reduces patient welfare.

On the other hand, prosecutors of hospice fraud whistleblowing cases allege that, in some circumstances, patients' families were not made aware that their relative would have to forgo life-prolonging care following hospice enrollment. If patients or their families did not understand that hospice patients face higher mortality risks, the welfare implications from expanding hospice are less clear.

While there is no comprehensive data on the share of hospice enrollees who do not understand the implications of enrollment, we can consider a very simple bounds analysis. Over the window between diagnosis and 5 years later, the average marginal hospice enrollee saves $45,300 and is 16.8% more likely to die. On average, compliers lose roughly 0.81 life-years in this window, as shown by Appendix Table A5, which reports the monthly change in life expectancy over 5 years using the same 2SLS design. If we are willing to consider death as a welfare cost only for those patients who enrolled unknowingly, the efficiency of for-profit hospice inducement of marginally eligible patients is governed by the tradeoff:

$$\$45{,}300 \geq 0.81 \times Value\ of\ LifeYear \times Share\ Uninformed \qquad (3)$$

Appendix Figure A3 shows the tradeoff between these parameters and displays the regions where expanded hospice enrollment is efficient or inefficient. The value of life year varies between $15,000 and $150,000, where the upper bound is in line with standard life-year estimates (ICER, 2020). As shown by Appendix Figure A3, for most reasonable ranges of the value of a life-year for end-of-life ADRD patients, a high share of patients would need to be uninformed that hospice increases the risk of death – despite signing paperwork agreeing to forgo curative care – for this regime to be inefficient. Moreover, if the value of the lost 0.8 life-years was worth less than $45,300 – a reasonable estimate given the low quality of life for end-of-life ADRD patients – this tradeoff is welfare-improving even if we consider death a cost for all patients regardless of if they made an informed decision.

Finally, there are reasons to believe the welfare gains from ADRD enrollment in hospice are even higher than those reported here. First, many patients (and their family members) report high satisfaction with hospice, and therefore it could improve quality of life even if total life expectancy falls. Indeed, this is one of the primary motivations for hospice. Second, the cost savings as measured in this paper are only the cost savings from the Medicare program. Most of the ADRD patients in our sample collect Social Security, and many live in Medicaid-funded long term care facilities. The estimates of cost savings presented here do not include the potential gains from lower expenditure by these other social programs.

Our analysis of the implications of higher death rates is rudimentary and is not the primary focus of our analysis, which is instead focused on costs. We offer these calculations and arguments to illustrate that a strong case must be made that decisions about hospice enrollment are suboptimal for the cost savings of the program not to exceed potential costs to the uninformed.

The estimates presented above address the broad question of whether the government should adopt a more or less permissive approach to hospice use by ADRD patients. But the government has only a limited set of tools at its disposal to affect hospice use, and the types of patients affected by these policies may differ from the set of patients induced to enroll in hospice by the entry of for-profit firms. Thus, it is important to evaluate these policies in their own right. Below, we focus on two: the hospice cap and antifraud litigation.

5. The Hospice Cap

One longstanding policy designed to limit the overuse of hospice is a cap on hospices' revenues based on the number of patients they serve. In 2016, the cap was $27,820 per patient. However, the cap is applied at the firm level, not the patient level, and so short stay and long staying patients can balance each other out. For example, a hospice that served 100 patients would face a cap of $27,820 × 100. The cap binds sharply: if a hospice received payments from Medicare that exceeded this amount, it would have to refund the entire difference to Medicare. Payments to hospices are measured over the cap year, which runs from November 1 to October 31 the following year. Appendix C presents more institutional details about the cap calculation.

5.1 Cap and Firm Profit Status

The cap is designed to reduce hospices' incentives to treat long-stay patients, and we show that it binds more strictly for for-profit hospice firms. Using the universe of hospice claims for Medicare beneficiaries from 1999 to 2019, we create a dataset at the hospice-year level. Our data contain 27,871 for-profit hospice years and 26,987 non-profit hospice years. We exclude hospices with an average annual census of ten or fewer patients during the period in which they are present in data. We also exclude hospices' first and last years in business for hospices that entered or exited during the study period, as they might not have had a full cap year with which to compute data.

For each hospice-year, we calculate the ratio of received revenues to the hospice's cap (the per patient cap multiplied by the number of patients admitted). Figure 3 shows the histogram of the cap ratio by ownership status. For-profit hospices are much more likely to exceed the cap (18.3%) compared to non-profit hospices (3.7%). The proportion of for-profit hospices that exceed that cap at least once during the period in which they appear in our data is 24.7% (N = 2,704) for for-profit hospices and 10.8% (N = 2,185) for non-profit hospices.

Figure 3 also reveals a distinct lack of "bunching" at the cap threshold. Hospices' inability to maintain revenues just below the cap may reflect the difficulty of making short-term adjustments to their average length of stay and predicting future revenues and patient length of stays. Hospices' referral relationships with hospitals, nursing homes, oncologists, and other providers take time to develop. Faced with cap pressure, hospices cannot suddenly request an

inflow of short-stay patients to balance out the stays of patients who survive longer than expected. Hospices can and do discharge patients alive, but hospices that discharge too many patients may harm their reputations and jeopardize future referrals. Hospice consultants encourage hospices to monitor their proximity to the cap. But even the best predictions are subject to substantial error, and hospices may rely on back-of-the-envelope calculations that add additional prediction errors.

Firms face uncertainty in their proximity to the aggregate cap, based on the longevity of their patient population. Appendix Table A6 shows the inability of firms to predict patient stay length. We regress patient stay length in hospice, or an indicator variable for a stay over 180 days, on a patient's chronic condition indicators and demographics. The R^2 estimate of these regressions is between 0.005 and 0.015, indicating the error inherent predicting long stays.

5.2 Effects of Cap on Spending and Patient Care

In light of our findings that ADRD admission saves federal money among potentially long-staying patients, we want to evaluate the spending and health effects of the cap, a tool designed to limit long hospice stays.

We begin with a sample of all patient-months in hospice from 2000 through 2019, with 53 million patient-months, and consider patient spending, care, and health outcomes in the 12-month period following each patient-month in hospice as a function of the patients' hospices' proximity to the cap in that month. Appendix C provides details on the sample construction. A primary threat to identification is that hospices which admit long-staying patients, leading to higher cap proximity, may be different along many dimensions than those that do not. Therefore, we consider a *within-hospice-year* regression, conducted at the patient-month level:

$$Y_{imLk} = a + \beta OverCap_{kLm} + \eta_{kL} + \gamma_{Lm} + Staylength_{im} + \epsilon_{imk} \quad (4)$$

Here, Y_{imLk} includes outcome variables such as patient spending and care in the subsequent 12 months for patient i in month m of year L at hospice k. $OverCap_{kLm}$ is hospice k's predicted probability of exceeding the cap in year L, as observed in a given month m in year L, based on the cumulative level of spending per patient up to that month. We use a linear probability model on the universe of hospice months to estimate a firm's probability of exceeding a cap based on

its revenue and patient count in that month (see Appendix C for details). The inclusion of hospice-year fixed effects allows us to compare patients from within the same firm in the same year, controlling for seasonal trends with year-month fixed effects and patient length-of-stay fixed effects $Staylength_{im}$. Standard errors are clustered at the hospice firm level. This specification identifies the effect of quasi-random cap pressure driven *not* by a hospice's long-term admission patterns but rather the fact that some of their patients *happened* to live longer than anticipated.

Table 5 presents estimates of β from equation (4), with spending outcomes over a 12-month period following each patient-month. When a firm faces the cap, patient spending is reduced by $2,300 over the subsequent 12 months. This is nearly entirely driven by a reduction in hospice spending, although there is a small but statistically significant increase in home health spending, reflecting the substitutability of home health and hospice care. There are no effects on skilled nursing facility, outpatient, and inpatient spending.

Table 6 presents estimates from equation 4 for a number of different outcomes reflecting hospice care choices and patient health that may respond to cap pressure. When facing cap pressure, patients are substantially more likely to be discharged alive, an increase of 1.57 percentage points from a baseline mean of 5.2%. Patients are also less likely to receive inpatient hospice: spending on inpatient hospice decreases by $2.50 from a baseline mean of $17 over 12 months (a -15% change; inpatient hospice is an infrequently used short-term option for patients facing acute crises).

Finally, and most worrisome, Table 6 shows that patient mortality increases by 2 percentage points in response to cap pressure from a baseline of 75%. Deaths caused by cap pressure can be due either to changes in care within the hospice – such as shirking on patient care – or as a consequence of harmful care transitions that occur when patients are discharged alive from hospice. Unlike hospice enrollment, where patients anticipate that they will face a higher risk of death, cap pressure potentially results in lower quality care and unanticipated increases in mortality risk. Disruptive care transitions among an already high-mortality population are a potentially welfare-reducing feature that saves relatively low amounts of money and may also cause lower quality of life during the period before death.

5.3 Discussion

The hospice aggregate cap distorts patient care, with the goal of deterring the use of hospice for long-staying patients. However, our results have shown that hospice is cost-saving, even for the marginally eligible and often long-staying ADRD population. In light of those findings, the fact that the cap is so disruptive to patient care, causing live discharges among a sick population and increasing the probability of death, indicates that the cap may be an inefficient way to regulate hospices. These are particularly important results in light of recent calls by MedPAC to *lower* the hospice cap, which would increase the cap pressure on hospices. (MedPAC, 2021).

6. Anti-Fraud Lawsuits and Hospice Behavior

Another major policy used to combat "overuse" of hospice is the federal False Claims Act, an anti-fraud statute that provides civil penalties for firms that violate Medicare billing standards. False Claims Act lawsuits have targeted hospice firms – mainly, though not exclusively, for-profit firms– for admitting non-terminal patients or, at the 6-month mark, recertifying these patients as terminal for another 6 months of eligibility. These firms face legal action in federal civil court, which can end with large settlements or penalties equal to treble the amount of fraudulent billings plus a fine of roughly $11,000 per claim. False Claims Act civil lawsuits are generally settled or dismissed; few go to trial. For a deeper treatment of the economics of the False Claims Act, see (Leder-Luis, 2019).

The over-admission of ADRD patients has been a major source of litigation against hospice companies. For example, in a False Claims Act lawsuit against Evercare, a multi-state hospice chain, the civil complaint states:

> *"Defendants targeted for admission ineligible elderly patients with conditions like debility, dementia, Alzheimer's and cardiac or pulmonary irregularities that while serious were not likely to lead to the death of the patient within six months."*

This lawsuit settled for $18 Million in 2016. Similar allegations have been made in dozens of other False Claims Act cases.

Appendix Table A7 provides descriptive statistics about these cases, using data from a Freedom of Information Act request we filed with the Department of Justice. Of the 163 cases, 37% have been settled for a total of $351 million. Lawsuits have occurred from 1998 through

2021, spanning our entire sample period. These 163 cases are often against large chains, encompassing multiple individual hospice locations. Appendix D describes the matching process between the Freedom of Information Act Request and the Medicare data to identify prosecuted firms.

The use of anti-fraud litigation against hospice firms has been a source of major controversy. Different federal appellate courts have established different standards for determining whether admissions are fraudulent. At issue is the inherent subjectivity of determining whether patients have less than 6 months left to life and whether hospices' certification of eligibility can ever be "false" given that life expectancy is an error-prone prediction, not a concrete fact. (West, 2021). This unresolved case law highlights the importance of understanding the effect of hospice use, and the impact of civil litigation, on the ADRD and hospice population.

6.1 Effect of Litigation on Firm Behavior

We consider the effects of False Claims Act civil anti-fraud lawsuits on firm behavior. Firms that are sued may admit fewer long-staying patients and ADRD patients due to the direct intervention of the federal government in enforcing the hospice eligibility rules with civil penalties. Lawsuits could unintentionally increase Medicare costs if they inhibit the use of hospice care by patients for whom hospice care would be cost saving.

It is important to note the strong relationship between ADRD diagnosis and long stays: 52.9% of hospice episodes over 180 days are among patients with an ADRD diagnosis at time of admission. While hospices may not be able to accurately predict patient stay length, as shown in Table A6 and discussed in Section 5.1, ADRD diagnosis is a highly predictive criteria for long stays. As such, reductions in long-staying patients to comply with regulatory pressure may entail costly reductions in ADRD hospice usage.

We use a sample of all hospice years from 2000 to 2019 and create a firm-year level dataset. We evaluate the impact of litigation on hospices' share of patients who stay above 180 days, the share of patients with different diagnoses in the year before coming to hospice, hospices' mean length of stay, and live discharge rates. For each hospice year, we consider whether the hospice was sued and when using data from the FOIA request we filed with the Department of Justice. We restrict our sample to 10 years before and after a lawsuit is filed for

sued firms and use the full panel for untreated firms. Our sample contains about 66,700 hospice years.

We employ a difference-in-difference identification strategy that exploits the differences in timing of when hospice firms are sued. Specifically, we estimate:

$$Y_{ht} = \alpha + \beta D_{ht} + \gamma_h + \eta_t + \varepsilon_{ht} \qquad (5)$$

Where Y_{ht} is an outcome for hospice h at year-month t; D_{ht} is an indicator for whether hospice h at year t had been sued; and γ_h and η_t are provider and year-month fixed effects. The coefficient of interest is β, which captures the effect of being sued on the hospice-level outcome.

Table 7 presents the results of the difference-in-difference specification (5) on the firm-level patient population for each outcome. Being sued causes hospices to decrease the share of patients staying over 180 days by 1.3 percentage points from a mean of 13.4%, and average length of stay falls by 6.8 days from a mean of 84 days. Sued firms reduce their share of ADRD patients by 1.4 percentage point from a baseline mean of 35% in the years following their lawsuit. Interestingly, the proportion of patients who are discharged alive declines by 1.6 percentage points from a mean of 22%. After being sued, hospices may admit fewer non-terminally ill patients.

In contrast, lawsuits against firms cause these firms to accept more cancer patients. The shift from ADRD patients to cancer patients reflects the fact that cancer patients have a more predictable prognosis, and there is less uncertainty over whether they are eligible for hospice under Medicare's coverage rules. Like ADRD patients, cancer patients also save money through hospice enrollment: Appendix Table A8 repeats the distance-based analysis from Section 4 on the sample of patients with cancer diagnoses. The exposure of cancer patients to for-profit hospice increases hospice usage in the first stage, reduces five-year spending, and increases mortality. Five-year spending decreases by $83,000 among compliers, while fine-year mortality rises by 28 percentage points. The savings are largely due to a reduction in spending on pharmaceuticals.

The results from our event study show that, following a lawsuit, firms are less likely to accept ADRD and long-staying patients. Given that ADRD patients save money on average, it appears that lawsuits limiting their exposure to hospice care are cost-increasing. However, this

conclusion assumes that the lawsuits are not well targeted – that is, that they do not selectively forgo admitting particularly inappropriate patients.

To examine this hypothesis, we conduct a heterogeneity analysis. We break ADRD hospice patients by their spending in the year before hospice admission and repeat the difference-in-difference design of Equation (5). Appendix Table A9 presents the results. Lawsuits reduce hospice use even among patients in the top quintile of pre-hospice spending, although the effects are somewhat stronger for lower-cost patients. These results indicate that anti-fraud lawsuits against hospice firms deter hospice usage even among patients for whom hospice has the greatest opportunity for cost savings.

For completeness, we also evaluate the effects of lawsuits on patient mix and length of stay using event study specifications. We estimate:

$$Y_{ht} = \alpha + \sum_{\tau \in [-5,5], \tau \neq -1} \beta_\tau D_{h\tau} + \gamma_h + \eta_{tm} + \varepsilon_{ht} \qquad (6)$$

We include dynamic estimates of the effects in the 5 years before and after the hospice is sued, and we include firm and year-month fixed effects. We present the estimates of β_τ, where the outcome is the share of long-staying patients and ADRD patients, as event study figures in Figure 4. The results match the results presented in Table 7 and show that the proportions of long-stay patients and ADRD patients decline following lawsuits. Appendix Figure A4 presents event study figures for additional outcomes including the share of cancer patients and the average length of stay. Appendix Figure A5 repeats this specification to account for modern critiques of two-way fixed effects designs, following (Sun & Abraham, 2021). Our results are robust to this alternative approach.

6.3 Discussion

Our results show that, in general, anti-fraud lawsuits inhibit the use of hospice for long-staying patients and ADRD patients, for whom we estimate that hospice enrollment reduces Medicare spending. Sued firms increase compliance with eligibility rules, decreasing the share of patients who stay over 180 days, and substitute away from ADRD patients, who are most likely to experience longer stays. They appear to reduce admissions of ADRD patients across the spending distribution, rather than only restricting enrollment of ADRD patients with the best

prognoses. This result should be interpreted cautiously, however, because pre-hospice spending may be only a weak signal of life expectancy.

It is an open question *why* litigation against hospice firms changes their behavior. Rational firms would not over-admit patients in the first place if the threat of litigation and expected penalty were high enough. However, our findings are in line with previous studies that show large effects from realized lawsuits (Howard & McCarthy, 2021; Leder-Luis, 2019). In the case of hospice fraud, one potential mechanism is the use of corporate integrity agreements, a form of increased monitoring which firms often agree to while signing False Claims Act settlements. Firms may also believe that the profits from fraudulent admissions are high enough to outweigh the expected cost of settlements, and it is only when facing increased scrutiny that they must comply with eligibility standards.

In the short term, reallocating hospice capacity away from ADRD patients and towards cancer patients could reduce Medicare spending, in so much as the cancer patients save even more money than ADRD patients. But the longer-term general equilibrium effects may go in the opposite direction. Exposure to hospice is not zero sum, as evidenced by the expansion of hospice in Figure 1. Enrollment of ADRD patients in hospice reduces government spending relative to the outside option of remaining in the costlier traditional health care system. Deterring the use of hospice by ADRD patients would therefore result in more costly longer-term care.

Our results caution against aggressive civil prosecution of purportedly fraudulent behavior without consideration of its effects on health spending. Hospice litigation is a case where the government's anti-fraud crackdowns potentially increased spending by deterring cost-effective care. These results stand in contrast to existing work on fraud enforcement, which largely shows high levels of cost savings.

7. Conclusion

More than 50% of Medicare decedents use hospice services every year. Over the past 20 years, the market for hospice has grown extensively, largely driven by the entry of for-profit hospice firms and the use of hospice by patients with ADRD. Using patient exposure to for-profit hospice as an instrument, we provide the first causal evidence on the effects of hospice usage among marginally eligible ADRD patients.

We estimate that hospice enrollment of the marginal patient reduces costs by about $45,000 over 5 years, driven by large reductions in inpatient, skilled nursing, home health, and pharmaceutical spending that far offset the increased spending on hospice. While hospice enrollment also reduces patient longevity, it is nevertheless welfare-improving for reasonable values of the willingness-to-pay for an ADRD quality-adjusted life year, especially in light of the fact that these patients elect to forgo curative care in favor of hospice. However, a full treatment of the relevant ethical questions is beyond the scope of this paper.

If hospice enrollment is welfare-improving, then policies that limit hospice use on the margin may be inefficient. We find that aggregate cap on hospice revenues distorts patient care, increasing live discharges and patient mortality in return for minimal savings. We also find that anti-fraud lawsuits against firms for potentially inappropriate hospice use end up reducing hospice use by long-staying patients and ADRD patients. They may cost the government money relative to the alternative or keeping these patients in the hospice program. While for-profit admission of ADRD patients without an acutely terminal diagnosis may be considered fraudulent or improper under current coverage rules, our results suggest that the problem may lie not with firm behavior but with the rules themselves.

More generally, our findings raise a host of interesting policy questions for the hospice sector. Given the flaws we find in the current system, how should the government encourage the use of hospice for well-informed patients who are at the end of life while ensuring that there is not overuse on the margin? Would a different cap structure, or different standards for fraudulent firm behavior, be more efficient? These are important topics for future research.

The use of for-profit hospice for ADRD patients provides lessons beyond the $20 billion hospice industry. While recent studies have largely found negative effects of for-profit care, the hospice industry demonstrates that for-profit care can in fact save money if it is a substitute for even more expensive alternatives. This underscores the importance of measuring general equilibrium effects like total expenditure when evaluating the impact of a particular form of medical care.

Bibliography

Centers for Medicare & Medicaid Services. (2015, 05 05). *Medicare Program; FY 2016 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Requirements*. Retrieved 12 22, 2022, from Federal Register: https://www.federalregister.gov/documents/2015/05/05/2015-10422/medicare-program-fy-2016-hospice-wage-index-and-payment-rate-update-and-hospice-quality-reporting

Alam, R. (2022). *Quality choice with reputation effects: Evidence from hospices in California.* Working Paper.

Aldridge Carlson, M. D., Barry, C. L., Cherlin, E. J., McCorkle, R., & Bradley, E. H. (2012). Hospices' Enrollment Policies May Contribute To Underuse Of Hospice Care In The United States. *Health Affairs*, 2690-2698.

Aldridge, M., Moreno, J., & McKendrick, K. (2022). Association Between Hospice Enrollment and Total Health Care Costs for Insurers and Families, 2002-2018. *JAMA Health Forum, 3*(2).

Ata, B., Killaly, B. L., Olsen, T. L., & Parker, R. P. (2012). On Hospice Operations Under Medicare Reimbursement Policies. *Management Science*, 1027-1044.

Braun, R. T., Stevenson, D. G., & Unruh, M. A. (2021). Acquisitions of Hospice Agencies by Private Equity Firms and Publicly Traded Corporations. *JAMA Internal Medicine*, 1113-1114.

Chung, A., & Sorensen, A. (2018). *For-Profit Entry and Market Expansion in the Hospice Industry.* Working Paper.

Cuppett, W. T., & Forster, T. M. (2014). *How to Master Hospice Hospice Aggregate Aggregate CAP Reporting Reporting and Financial Management.* National Association for Home Care & Hospice. Phoenix: NAHC 2014 Annual Meeting.

Dalton, C. M., & Bradford, W. D. (2019). Better together: Coexistence of for-profit and nonprofit firms with an application to the US hospice industry. *Journal of Health Economics*, 1-18.

Davis, F. A. (1988). Medicare hospice benefit: Early program experiences . *Health Care Finance Review*, 99-111.

Dolin, R., Silberman, P., Kirk, D. A., Stearns, S. C., Hanson, L. C., Taylor, D. H., & Holmes, G. M. (2018). Do Live Discharge Rates Increase as Hospices Approach Their Medicare Aggregate Payment Caps? Author links open overlay panel. *Journal of Pain and Symptom Management*, 775-784.

Einav, L., Finkelstein, A., Mullainathan, S., & Obermeyer, Z. (2018). Predictive modeling of U.S. health care spending in late life. *Science, 360*(6396), 1462-1465 .

Fowler, A. C., Grabowski, D. C., Gambrel, R. J., Huskamp, H. A., & Stevenson, D. G. (2017). Corporate Investors Increased Common Ownership In Hospitals And The Postacute Care And Hospice Sectors. *Health Affairs*, 1547-1555.

Gandhi, A., Song, Y., & Upadrashta, P. (2022). Private Equity, Consumers, and Competition. *SSRN*.

Gandhi, S. O. (2012). Differences between non-profit and for-profit hospices: patient selection and quality. *International Journal of Health Care Finance and Economics*, 107-127.

Gianattasio, K. Z., Ali, M., Lupu, D., Prather, C., & Power, M. C. (2022). Evaluation of Federal Policy Changes to the Hospice Benefit and Use of Hospice for Persons with ADRD. *JAMA Health Forum*, e220900.

Gonda, S., & Song, Z. (2019). Potential Implications of Private Equity Investments in Health Care Delivery. *JAMA*, 1047-1048.

Gozalo, P., Mlotzke, M., Mor, V., Miller, S. C., & Teno, J. M. (2015). Changes in Medicare Costs with the Growth of Hospice Care in Nursing Homes. *New England Journal of Medicine*, 1823-1831.

Greer, D. S., Mor, V., Morris, J. N., Sheroowd, S., Kidder, D., & Birnbaum, H. (1986). An alternative in terminal care: Results of the national hospice study. *Journal of Chronic Diseases*, 9-26.

Gupta, A., Howell, S. T., Yannelis, C., & Abhinav, G. (2021). Does Private Equity Investment in Healthcare Benefit Patients? Evidence from Nursing Homes. *NBER Working Paper*.

Harrison, K. L., Cenzer, I., Ankuda, C. K., Hunt, L. J., & Aldridge, M. D. (2022). Hospice Improves Care Quality for HOlder Adults with Dementia in their Last Month of Life. *Health Affairs (Millwood)*, 821-830.

Harrison, K. L., Cenzer, I., Ankuda, C. K., Hunt, L. J., & Aldridge, M. D. (2022). Hospice improves care quality for older adults with dementia in their last month of life. *Health Affairs*, 821-830.

Ho, V. (1991). *The Medicare Hospice Benefit: The Effectiveness of Price Incentives in Health Care Policy.* Stanford University Dissertation.

Hogan Lovells FCA Alert. (2019, September 9). *Hogan Lovells Publications*. Retrieved December 23, 2022, from https://www.hoganlovells.com/en/publications/eleventh-circuit-confirms-mere-difference-of-opinion-between-physicians

Hogan, C., & Neuman, K. (2015). *Spending in the Last Year of LIfe and the Impact of Hospice on Medicare Outlays.* Washington, D.C.: MedPAC.

Howard, D. (2020). False claims act liability for overtreatment. *Journal of Health Politics, Policy and Law*, 419-437.

Howard, D. (2020). False Claims Act Liability for Overtreatment. *Journal of Health Politics, Policy and Law* , 419-437.

Howard, D., & McCarthy, I. (2021). Deterrence effects of antifraud and abuse enforcement in health care. *Journal of Health Economics*.

Huskamp, H. A., Newhouse, J. P., Norcini, J. C., & Keating, N. L. (2008). Variation in patients' hospice costs. *INQUIRY: The Journal of Health Care Organization, Provision, and Financing*, 232--244.

ICER. (2020, January 31). *2020-2023 Value Assessment Framework.* Retrieved from Institute for Clinical and Economic Review: https://icer.org/wp-content/uploads/2020/11/ICER_2020_2023_VAF_02032022.pdf

Kelley, A., Deb, P., Du, Q., Aldrige Carlson, M., & Morrison, R. (2013, March). Hospice Enrollment Saves Money For Medicare And Improves Care Quality Across A Number Of Different Lengths-Of-Stay . *Health Affairs, 32*(3), 552-561.

Kofman, A. (2022, November 28). How Hospice Became a For-Profit Hustle . *The New Yorker*.

Krant, M. (1978). The hospice movement. *New England Journal of Medicine*.

Leder-Luis, J. (2019). Can Whistleblowers Root Out Public Expenditure Fraud? Evidence from Medicare. *Working Paper*.

Leibowitz, A. A., Tan, D., & Gildner, J. L. (2020). The Effect of Hospice on End-of-Life Costs for Terminal Medicare Patients with HIV. *INQUIRY: The Journal of Health Care Organization, Provision, and Financing*, 57.

Lindrooth, R. C., & Weisbrod, B. A. (2007). Do religious nonprofit and for-profit organizations respond differently to financial incentives? The hospice industry. *Journal of Health Economics*, 342-357.

MedPAC. (2004). *Hospice care in Medicare: Recent trends and a review of the issues.* Report to the Congress: New Approaches in Medicare .

MedPAC. (2006, June). *Report to the Congress. Increasing the Value of Medicare.* Retrieved from Medicare Payment Advisory Commission: https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/reports/Jun06_EntireReport.pdf

MedPAC. (2021, June). *Congressional request: Private equity and Medicare.* Retrieved from Medicare Payment Advisory Commission: https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/default-document-library/jun21_ch3_medpac_report_to_congress_sec.pdf

MedPAC. (2021). *Report to the Congress: Medicare Payment Policy. Chapter 11, Hospice Services.*

National Hospice and Palliative Care Organization. (2020). *NHPCO Facts and Figures.* Retrieved from https://www.nhpco.org/wp-content/uploads/NHPCO-Facts-Figures-2020-edition.pdf

O'Malley, A., Bubolz, T., & Skinner, J. (2021). *The Diffusion of Health Care Fraud: A Network Analysis.* National Bureau of Economic Research Working Paper.

Plotzke, M., Christian, T., Axelrod, E., Hunt, M., & Muma, A. (2015, December 3). *Medicare Hospice Payment Reform: Analysis of How the Medicare Hospice Benefit is Used.* Retrieved from Abt Associates: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Hospice/Downloads/December-2015-Technical-Report.pdf

Porter, E. (2012, August 21). Rationing Health Care More Fairly . *The New York Times*.

Stevenson, D. G., Sinclair, N., Zhang, S., Meneades, L. M., & Huskamp, H. A. (2020). Trends in Contracting and Common Ownership Between Hospice Agencies and Nursing Homes. *Medical Care*, 329-335.

Sun, L., & Abraham, S. (2021). Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. *Journal of Econometrics, 225*(2), 175-199.


Taylor Jr, D. H., Ostermann, J., Van Houtven, C. H., Tulsky, J. A., & Steinhauser, K. (2007). What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? *Social sciences and medicine*, 1466-1478.

Wachterman, M. W., Marcantonio, E. R., & Davis, R. B. (2011). Association of Hospice Agency Profit Status with Patient Diagnosis, Location of Care, and Length of Stay. *JAMA*, 472-479.

West, S. (2021). Proof of Objective Falsehood: Liability under the False Claims Act for Hospice Providers. *University of Cincinnati Law Review* , 328.


Tables and Figures

Figure 1: Proliferation of Hospice Over Time




Notes: This figure shows the expansion of hospice over time. The left panel shows the number of hospices that serve Medicare patients, by profit status and year. The right panel shows the share of Alzheimer's and Dementia patient-years that contain at least one hospice claim over time.

Figure 2: First Stage Event Study



Notes: The figure shows the coefficient estimates and 95% confidence intervals for an event study specification related to our first stage. Appendix B provides details of the specification. We show the effect on ADRD patient hospice usage in a zip code when the nearest for-profit hospice moves from greater than 50 miles away to less than 10 miles away. The regression is conducted at the zip-year level with zip and year fixed effects as well as zip-specific linear time trends. Appendix Figure A2 repeats this estimate with other estimators robust to critiques of two-way fixed effects models.


Figure 3: Histogram of hospice Revenue Relative to the Cap by Ownership Type




Notes: The graph shows histograms of hospices' annual cap-year revenues as a percent of the aggregate cap, by for-profit status. The aggregate cap was calculated by multiplying the number of admissions during the cap year by the per patient cap in a given year. Data were winsorized at 200%. Appendix C provides additional details of the cap calculation.

Figure 4: Event-Study Estimates of Impact of Lawsuits

4A. Effect of Lawsuit on Patients Staying Over 6 Months



4B. Effect of Lawsuit on Share ADRD



Note: These figures show outcomes of the event study described in equation (6). Specifically, the figures show the dynamic effects of a lawsuit in year 0 on the share of patients staying over 6 months (Panel A) and the share of patients with an ADRD diagnosis (Panel B). The points in the figure represent point estimates for each lag and lead around a hospice lawsuit, and the error bars correspond to 95% confidence intervals. Each event study is normalized such that the coefficient corresponding to year -1 is 0.

Table 1: Descriptive Statistics for ADRD Patient Sample

	Mean	SD
Male	0.38	0.49
Age at Diagnosis	81.04	9.75
White	0.86	0.35
Black	0.09	0.29
Hispanic	0.02	0.14
Other Race	0.03	0.17
Distance to FP Hospice (mi)	18.54	17.48
Year Diagnosed	2,006.56	4.38
Atrial Fibrillation	0.12	0.33
Cataracts	0.22	0.42
Chronic Kidney Disease	0.14	0.35
COPD	0.15	0.36
Heart Failure	0.26	0.44
Diabetes	0.27	0.45
Glaucoma	0.11	0.32
Hip Fracture	0.02	0.13
Ischemic Heart Disease	0.39	0.49
Depression	0.17	0.37
Osteoperosis	0.09	0.28
Rheumatoid Arthritis	0.31	0.46
Stroke / Transiet Ischemic Attack	0.09	0.28
Breast Cancer	0.03	0.16
Colorectal Cancer	0.02	0.13
Lung Cancer	0.01	0.09
Prostate Cancer	0.04	0.19
Endometrial Cancer	0.00	0.05
Anemia	0.31	0.46
Asthma	0.04	0.20
Hyperlipidemia	0.34	0.47
Benign Prostatic Hyperplasia	0.06	0.24
Hypertension	0.59	0.49
Acquired Hypothyroidism	0.10	0.30
Went to Hospice within 5Y	0.33	0.47
Died within 5Y	0.70	0.46

Note: N=10854784

Notes: This table describes the characteristics of ADRD patients in our sample (N = 10,854,784). For binary variables, the mean is the share of the sample that matches that description. Chronic conditions are measured in the year prior to ADRD diagnosis.

Table 2: First Stage Estimates

Dependent Variables:	Went to Hospice	Hospice Pmt	Hospice LOS
Model:	(1)	(2)	(3)
Variables			
Forprofit Distance (10mi)	-0.0057***	-76.96***	-0.6933***
	(0.0003)	(9.614)	(0.0647)
Fixed-effects			
Demographics Controls	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes
Fit statistics			
Observations	10,856,191	10,856,191	10,856,191
R^2	0.09403	0.03077	0.02790
Within R^2	9.64×10^{-5}	1.25×10^{-5}	2.08×10^{-5}
Dependent variable mean	0.33012	4,846.6	32.007
Wald (joint nullity)	343.45	64.084	114.77

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table reports OLS estimates of equation (1). The dependent variables are measures of hospice use: an indicator for whether the patient went to hospice, Medicare spending on hospice, and number of days in hospice, all within years 0-5 of ADRD diagnosis. The independent variable is distance to for-profit hospice (scaled to 10 miles). Each regression includes controls for zip code, diagnosis year cohort, and patient characteristics (age, sex, race, chronic conditions) in the year before diagnosis. The negative sign indicates that, the further that a for-hospice is from a patient, the less likely they are to use hospice.

Table 3: IV Results for Medicare Spending Outcomes

Dependent Variables:	Total Pmt		Inpatient	Outpatient	Home Health
Model:	(1)	(2)	(3)	(4)	(5)
Variables					
Hospice Entry	13,173.6***	-45,329.4***	-9,393.4**	5,884.1***	-13,025.5***
	(67.47)	(7,584.4)	(3,709.2)	(1,355.7)	(1,949.6)
Fixed-effects					
Demographics Controls	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Estimate	OLS	IV	IV	IV	IV
Observations	10,856,191	10,856,191	10,856,191	10,856,191	10,856,191
R^2	0.21578	0.11983	0.13886	0.19879	-0.13698
Within R^2	0.00617	-0.11543	-0.01498	-0.04823	-0.27784
Dependent variable mean	80,867.7	80,867.7	30,811.7	6,668.2	5,623.9
Wald (2nd stage)		35.720	6.4135	18.836	44.637
Wald (1st stage), Hospice Entry		343.45	343.45	343.45	343.45

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Dependent Variables:	SNF	Part D	All Hospice	Forprofit Hospice	Nonprofit Hospice
Model:	(1)	(2)	(3)	(4)	(5)
Variables					
Hospice Entry	-22,498.3***	-10,333.7***	13,493.4***	22,103.4***	-8,415.3***
	(2,309.8)	(2,295.9)	(1,421.7)	(1,647.9)	(1,604.5)
Fixed-effects					
Demographics Controls	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Estimate	IV	IV	IV	IV	IV
Observations	10,856,191	10,856,191	10,856,191	10,856,191	10,856,191
R^2	-0.21925	0.07851	0.17537	-0.15091	-0.28483
Within R^2	-0.31619	-0.05280	0.14920	-0.18896	-0.31832
Dependent variable mean	12,701.8	5,633.3	4,846.6	2,539.5	2,291.6
Wald (2nd stage)	94.876	20.258	90.085	179.91	27.508
Wald (1st stage), Hospice Entry	343.45	343.45	343.45	343.45	343.45

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table reports 2SLS estimates of equation (2) for Medicare spending outcomes. Column 1 presents OLS estimates for total spending, for contrast. The dependent variables are categories of Medicare spending between years 0-5 of ADRD diagnosis. The endogenous variable is whether the patient went to hospice in years 0-5 of ADRD diagnosis, which is instrumented using distance to for-profit hospice in the 2SLS regressions. Each regression includes controls for zip code, diagnosis year cohort, and patient characteristics (age, sex, race, chronic conditions) in the year before diagnosis.

Table 4: IV Results for Mortality Outcomes

Dependent Variables: Model:	Died w/in 30D (1)	Died w/in 90D (2)	Died w/in 1Y (3)	Died w/in 2Y (4)	Died w/in 5Y (5)
Variables					
Hospice Entry	0.0326*	0.0913***	0.1364***	0.1467***	0.1681***
	(0.0184)	(0.0240)	(0.0319)	(0.0357)	(0.0342)
Fixed-effects					
Demographics Controls	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Estimate	IV	IV	IV	IV	IV
Observations	10,856,010	10,856,010	10,856,010	10,856,010	10,856,010
R^2	0.02354	0.03202	0.08300	0.12922	0.22644
Within R^2	-0.00758	-0.02017	-0.01371	0.00107	0.07504
Dependent variable mean	0.06837	0.12685	0.26285	0.38971	0.66547
Wald (2nd stage)	3.1415	14.427	18.298	16.871	24.193
Wald (1st stage), Hospice Entry	343.39	343.39	343.39	343.39	343.39

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table reports 2SLS estimates of equation (2) for patient health outcomes. The dependent variables are mortality in different periods after ADRD diagnosis. The endogenous variable is whether the patient went to hospice in years 0-5 of ADRD diagnosis, which is instrumented using distance to for-profit hospice in the 2SLS regressions. Each regression includes controls for zip code, diagnosis year cohort, and patient characteristics (age, sex, race, chronic conditions) in the year before diagnosis.

Table 5: Impact of Cap Proximity on Patient Spending

Dependent Variables:	Medicare Pmts	Outpatient	Inpatient	SNF	Hospice	HHA
Model:	(1)	(2)	(3)	(4)	(5)	(6)
Variables						
Pr(Over Cap at EOY)	-2,309.7***	-55.96*	-4.460	-0.9342	-2,265.9***	17.61***
	(103.6)	(28.84)	(15.66)	(4.122)	(93.97)	(4.362)
Fixed-effects						
Provider-Cap Year	Yes	Yes	Yes	Yes	Yes	Yes
Year-Month	Yes	Yes	Yes	Yes	Yes	Yes
Months in Hospice	Yes	Yes	Yes	Yes	Yes	Yes
Fit statistics						
Observations	53,272,138	53,272,138	53,272,138	53,272,138	53,272,138	53,272,138
R^2	0.15494	0.02229	0.01228	0.00877	0.18460	0.02131
Within R^2	6.58×10^{-5}	2.14×10^{-7}	4.91×10^{-9}	2.45×10^{-9}	9.16×10^{-5}	2.33×10^{-6}
Dependent variable mean	18,591.9	1,012.2	415.09	87.509	17,031.3	45.760
Wald (joint nullity)	496.85	3.7640	0.08113	0.05137	581.47	16.306
F-test	2.9555	0.36757	0.20048	0.14265	3.6494	0.35093

Clustered (Provider) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This tables presents estimates from Equation (4), which measures the effect of a firm's probability of exceeding the hospice revenue cap on patient spending outcomes over the subsequent 12 months. This regression is estimated at the patient-month level, with provider-year, year-month and stay length fixed effects. Standard errors are clustered at the hospice provider level.

Table 6: Impact of Cap Proximity on Patient Care

Dependent Variables:	Live Discharge	Died w/in 1Y	Hospice: Inpatient
Model:	(1)	(2)	(3)
Variables			
Pr(Over Cap at EOY)	0.0157***	0.0239***	-2.541***
	(0.0011)	(0.0014)	(0.5800)
Fixed-effects			
Provider-Cap Year	Yes	Yes	Yes
Year-Month	Yes	Yes	Yes
Months in Hospice	Yes	Yes	Yes
Fit statistics			
Observations	53,272,138	53,272,138	53,272,138
R^2	0.02025	0.12137	0.02277
Within R^2	2.84×10^{-5}	1.92×10^{-5}	7.22×10^{-7}
Dependent variable mean	0.05203	0.74833	16.937
Wald (joint nullity)	189.44	308.19	19.192
F-test	0.33312	2.2266	0.37556

Clustered (Provider) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This tables presents estimates from Equation (4), which measures the effect of a firm's probability of exceeding the hospice revenue cap on patient care outcomes over the subsequent 12 months. This regression is estimated at the patient-month level, with provider-year, year-month and stay length fixed effects. Standard errors are clustered at the hospice provider level.

Table 7: Impact of Lawsuits on Patient Composition

Dependent Variables:	Share with ADRD	Share with Cancer	Avg. LOS	Share LOS ¿= 180	Share Live Discharged
Model:	(1)	(2)	(3)	(4)	(5)
Variables					
Firm Sued	-0.0138***	0.0088***	-6.785***	-0.0133***	-0.0162***
	(0.0027)	(0.0014)	(1.117)	(0.0021)	(0.0035)
Fixed-effects					
provider	Yes	Yes	Yes	Yes	Yes
Year	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Observations	66,708	66,701	66,708	66,708	66,708
R^2	0.66756	0.52322	0.55641	0.53367	0.70607
Within R^2	0.00097	0.00085	0.00166	0.00135	0.00107
Dependent variable mean	0.34788	0.14588	83.637	0.13365	0.22390

Clustered (provider) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

*Note*s: This table presents results from five regressions each estimated using equation (5), a difference-in-difference specification that estimates firm-level responses to being sued. The regression is estimated at the hospice-year level. The dependent variables are the share of admissions with an ADRD diagnosis (Column 1), the share of admissions with a cancer diagnosis (Column 2), the average length of stay for admissions (Column 3), the share of stays with a length of stay over 180 days (Column 4), and the share of stays that ended with a live discharge (Column 5). Figure 4 and Appendix Figure A4 present event study figures of the same outcomes.

Appendix for Online Publication

Appendix A: Distance metric

Distance is measured as the miles between the centroid of a patient's home zip code to the centroid of the nearest for-profit hospice's zip code. When there is a for-profit hospice in a patient's zip code, this distance is 0. Because marginal miles above a certain distance are unlikely to matter, we truncate distance at 50 miles: i.e., those that do not have any for-profit hospice within 50 miles are coded as having a distance of 50.

Appendix B: First Stage Event Study Details

We present an event study to illustrate that distance to a for-profit hospice affects ADRD patients' likelihood of going to hospice. While our main specification uses the full richness of changes in distance, this event study estimates the effect of a large discrete jump in distance to a for-profit hospice. We define treatment as the year when a zip code has at least one for-profit hospice within 10 miles and no for-profit hospices within 50 miles in the previous year, i.e., when a zip code shifts from not having any nearby for-profit hospices to having one within 10 miles.

We use the following estimating equation:

$$Y_{zt} = \sum_{k=-5, k\neq -1}^{5} \beta_k D_k + \gamma_z + \gamma_{tm} + \varepsilon_{zt}$$

Where Y_{zt} is the outcome for zip code z in year t, D_k are a series of lags and leads around treatment, γ_z and γ_{tm} are zip code and year-month fixed effects, and ε_{zt} is a stochastic error term. Lags and leads are capped such that D_{-5} is 1 for all years 5 or more years before the treatment and D_{-5} is 1 for all years 5 or more years after the treatment. The coefficients of interest are β_k and are presented in an event study figure, Figure 2.

Appendix C: Additional Cap Details

C.1 Computing the Cap

Hospices are permitted to use varying methods for counting computing their cap, and the rules have changed over time. Under the "streamlined" method, hospices count the number of new patients admitted from September 28 in one year to September 27 the following year. Under the "proportional" method, hospices count patients fractionally based on the proportion of the stay at that hospice during the cap period. Our data do not report which method hospices use. Hospices exclusively used the streamlined method before 2011, when the proportional method was introduced and made the default. By 2013, only 486 hospices used the streamlined method (Centers for Medicare & Medicaid Services, 2015). Because the streamlined method is simpler than the proportional method and because the streamlined method was the only method used for the majority of our study period, we use the streamlined period to estimate hospices cap usage. Using this method, our estimates of the proportion of hospices that exceed the cap matches other sources closely, e.g., Cuppett & Forster (2014).

Because we consider how each hospice's proximity to the cap changes within each cap year, we measure Medicare payments to the hospice at the monthly rather than yearly level. To that end, for each hospice claim, we distribute the Medicare payment amount evenly across the months covered in that claim. For example, if a claim is for a hospice stay that lasts between January and March and has a Medicare payment amount of $900, we assign a $300 Medicare payment to January, February, and March for that hospice. Then, we aggregate payments at the hospice-month level to measure monthly Medicare payments.

C.2 Patient-Month Estimates

To construct the patient-month sample that estimates Equation (4), we use the following criteria. We start with cap years 2001 through 2019, where cap year 2001 began in October 2000 and cap year 2019 began in October 2018. The sample ends in December 2018 to ensure we can observe 12 months after a given month for spending and care outcomes. We restrict the sample to hospices not in their first cap year, because partial years distort the cap calculation. We consider a patient's first visit to hospice; patients who are live discharged and ever re-enter hospice are excluded. We also exclude patients whose death date is before the first of that month.

C.3 Probability of Exceeding the Cap

We use a logistic regression to calculate, for each hospice in each month, the probability that a hospice will be over the cap at the end of the year based upon all interactions between the month of the year and the ratio of payments to the cap in that month. Specifically, we estimate the following logistic regression:

$$Y_i = \alpha + \phi Share\ of\ Cap + \sum_{i=1}^{12} \beta_i Month_i + \sum_{i=1}^{12} \gamma_i Month_i \times Share\ of\ Cap +$$

Where, because this is a logistic regression, Y is the log odds ratio that the hospice will be over the cap at the end of the year, and the Share of Cap variable is the ratio of cumulative payments to the hospice up until that month to their cap allotment at that time, and Month is the calendar month. If there are no patients in a given month that count toward the hospice's patient total, but the hospice accrues revenue, the share of the cap is undefined (due to a divide by zero) and is therefore dropped. The regression is estimated on all hospice-months where the hospice is not in its first cap year. We use this regression to predict fitted values for the probability that the hospice will be over the cap.

Appendix D: Matching FOIA Data into Medicare Claims

This appendix describes the steps we took to identify hospices that were defendants, or owned by defendants, in False Claims Act lawsuits.

We began with a list of hospice names from the Freedom of Information Act request and hospice names from the Provider of Services File (which includes Medicare provider numbers that can be merged to claims.) We merged the lists on the basis of hospice names. We then performed a second merge on the basis of the first word in each hospice's name.

We then removed some hospices from the merged list because the first word in their name is the same as the first word in a defendant's name: hospices that begin with "San" that are not "San Diego", hospices that begin with "United" that are not "United Hospice", hospices that begin with "St." that are not "St. Joseph", hospices that begin with "New" that are not "New Century", hospices that begin with "Care" that are not "Care Alternatives", hospices that begin with "Home" that are not "Home Health and Hospice Care", and hospices that and begin with

"Heart" that are not "Heart 2 Heart" or "Heart to Heart." We also removed from the merged list hospices with the following phrases in their names: "Good Heart", "Good Journey" and "Good Will" (Good Samaritan and Good Shepherd were defendants).


We added to the merged list hospices with the following words in their names: Authoracare, Voyager, Midwest, Complete, Bluegrass, Arizona, Louisville, Comforter, Kansas, Alamance (the full name of these defendants begins with the word "Hospice").

We count all hospices in the final merged list as defendants.

The Freedom of Information Act request from the Department of Justice gives details about the timing of the lawsuit. We use the "date received" variable to identify the year in which the lawsuit was filed.


Appendix Tables and Figures

Figure A1. Geographic Trends in Hospices




Notes: This figure shows the number of hospices per 1 million residents in each of the 50 states in 2000, 2005, 2010, and 2014. The number of hospices is calculated from the Medicare Claims files, and state population is extracted from the St. Louis Federal Reserve State Population estimates.

Figure A2: First Stage Difference-in-Difference Alternative Methodology



Notes: The figure repeats the event study of Figure 2, but using the Sun & Abraham (2021) estimator. We plot the coefficient estimates and 95% confidence intervals for the event study specification related to our first stage. Appendix B provides details of the specification. We show the effect on ADRD patient hospice usage in a zip code when the nearest for-profit hospice moves from greater than 50 miles away to less than 10 miles away. The regression is conducted at the zip-year level with zip and year fixed effects as well as zip-specific linear time trends.


Figure A3: Welfare Bounds Calculations




Notes: This figure describes the tradeoff between cost-savings and mortality described in Equation (3). Hospice saves money for ADRD patients, but increases mortality; however, most patients voluntarily accept the reduction in curative care to improve quality of life. This figure shows the share of patients that would need to have been uninformed about the consequences of hospice – and therefore whose mortality should be counted as a cost – for the program to be inefficient. It is plotted against the value of a life-year. For most reasonable quality-adjusted estimates for the value of an ADRD patient's last months, this tradeoff is efficient.

Figure A4: Event Studies of Effects of Lawsuits on Patient Composition

A.4.A: Effect of Lawsuit on Share Cancer



A43.B Effect of Lawsuit on Average Length of Stay




Notes: These figures show more outcomes of the event study described in equation (6) and presented in Figure 4. Specifically, the figures show the dynamic effects of a lawsuit in year 0 on the share of admissions with a cancer diagnosis (Panel A) and the average length of stay for


admissions (Panel B). The points in the figure represent point estimates for each lag and lead around a hospice lawsuit, and the error bars correspond to 95% confidence intervals. Each event study is normalized such that the coefficient corresponding to year -1 is 0.

Figure A5: Event Studies of Effects of Lawsuits on Patient Composition with Alternative Specification


A5.A Stays Above 180 Days




A5.B Share of ADRD Patients



A5.C Average Length of Stay



A5.D Share Cancer



Notes: These figures show alternative specifications of the event study described in equation (6) and presented in Figures 4 and A4, using the estimator proposed in Sun and Abraham (2021). Panel A shows the effect on hospice stays over 180 days; panel B shows the effect on the share of a hospice's patients with an ADRD diagnosis; panel C shows the effect on average length of stay; and Panel D shows the effect on the share of patients with a cancer diagnosis.

Table A1: Concurrent Hospice and Hospitalization Discharges

	(1) Home	(2) Died	(3) Medical Facility	(4) Home - HHA	(5) Home - Hospice	(6) Home - Home
In Hospice at Discharge	0.0186***	0.0221***	-0.0406***	-0.0993***	0.235***	-0.118***
	(0.00109)	(0.000487)	(0.00111)	(0.000751)	(0.000284)	(0.000947)
Constant	0.376***	0.0494***	0.574***	0.129***	0.0155***	0.232***
	(0.0000722)	(0.0000323)	(0.0000737)	(0.0000498)	(0.0000189)	(0.0000629)
N	45187965	45187965	45187965	45187965	45187965	45187965
DV Mean	0.376	0.0495	0.574	0.128	0.0165	0.231

Standard errors in parentheses

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Notes: This table presents the correlation between being in hospice at the time of hospitalization discharge and different discharge types among ADRD patients. Each regression is estimated at the hospitalization level, using 100% samples of MedPAR hospitalizations involving a patient diagnosed with ADRD in any year before the visit. In each regression, the independent variable is whether the patient was enrolled in hospice at discharge. The dependent variable is the share of hospitalization discharges that were discharged to home (Column 1), died during hospitalization (Column 2), discharged to a medical facility (Column 3), discharged home under the care of a home health agency (Column 4), discharged home under the care of hospice (Column 5), and discharged home otherwise (Column 6).

Table A2: Robustness: IV Estimates for Hospice Effect on Spending and Mortality over [t,t+2]
Period

Dependent Variables:	Total Pmt		Inpatient	Outpatient	Home Health
Model:	(1)	(2)	(3)	(4)	(5)
Variables					
Hospice Entry	14,691.9***	-32,957.8***	-4,794.7	4,439.2***	-6,930.0***
	(53.04)	(6,401.7)	(3,627.6)	(1,153.6)	(1,541.3)
Fixed-effects					
Demographics Controls	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Estimate	OLS	IV	IV	IV	IV
Observations	13,153,744	13,153,744	13,153,744	13,153,744	13,153,744
R^2	0.22608	0.14483	0.13238	0.25214	0.00109
Within R^2	0.00988	-0.09407	-0.00900	-0.04368	-0.12486
Dependent variable mean	59,097.3	59,097.3	23,950.1	4,959.4	4,011.6
Wald (2nd stage)		26.505	1.7470	14.809	20.215
Wald (1st stage), Hospice Entry		424.59	424.59	424.59	424.59

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Dependent Variables:	SNF	Part D	All Hospice	Forprofit Hospice	Nonprofit Hospice
Model:	(1)	(2)	(3)	(4)	(5)
Variables					
Hospice Entry	-20,538.3***	-10,296.0***	13,112.5***	23,456.4***	-10,261.2***
	(2,142.5)	(1,770.0)	(1,021.7)	(1,347.6)	(1,328.6)
Fixed-effects					
Demographics Controls	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes
Fit statistics					
Estimate	IV	IV	IV	IV	IV
Observations	13,153,744	13,153,744	13,153,744	13,153,744	13,153,744
R^2	-0.22380	0.02440	0.19910	-0.43977	-0.56038
Within R^2	-0.32211	-0.07079	0.17752	-0.47555	-0.59313
Dependent variable mean	9,498.0	3,545.7	2,733.5	1,397.3	1,328.2
Wald (2nd stage)	91.891	33.838	164.72	302.98	59.652
Wald (1st stage), Hospice Entry	424.59	424.59	424.59	424.59	424.59

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Dependent Variables: Model:	Died w/in 30D (1)	Died w/in 90D (2)	Died w/in 1Y (3)	Died w/in 2Y (4)
Variables				
Hospice Entry	0.0061	0.0883***	0.1371***	0.1733***
	(0.0200)	(0.0259)	(0.0339)	(0.0376)
Fixed-effects				
Demographics Controls	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes
Fit statistics				
Estimate	IV	IV	IV	IV
Observations	13,153,502	13,153,502	13,153,502	13,153,502
R^2	0.03164	0.06259	0.13578	0.20658
Within R^2	0.00088	0.01219	0.04474	0.08925
Dependent variable mean	0.07017	0.12846	0.26264	0.38740
Wald (2nd stage)	0.09352	11.622	16.391	21.250
Wald (1st stage), Hospice Entry	424.60	424.60	424.60	424.60

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table repeats instrumental variables estimates from equations (1) and (2) on mortality and spending outcomes, using a shorter window, [t, t+2] after a patient is diagnosed with ADRD. The results are very similar to the main specification presented in Tables 3 and 4.

Table A3. Robustness: IV Estimates for Hospice Effect on Spending and Mortality Among Non-Movers

Dependent Variables:	Hospice Entry	Total Pmt		Inpatient	Outpatient	Home Health	SNF	All Hospice	Forprofit Hospice	Nonprofit Hospice	Died w/in 5Y
Model:	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
Variables											
Forprofit Distance (10mi)	-0.0026***										
	(0.0003)										
Hospice Entry		13,141.8***	-83,057.7***	-12,982.4*	14,803.0**	-8,858.9***	-24,100.4***	11,923.3***	33,475.9***	-21,176.1***	0.2919***
		(92.67)	(17,986.3)	(7,873.2)	(6,403.2)	(2,082.3)	(3,543.2)	(1,880.9)	(3,581.9)	(3,463.4)	(0.0850)
Fixed-effects											
Demographics Controls	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fit statistics											
Estimate	OLS	OLS	IV	IV	IV	IV	IV	IV	IV	IV	IV
Observations	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,865,641
R^2	0.07682	0.14618	-0.12666	0.06827	0.06783	-0.17968	-0.66381	0.16170	-3.2817	-2.2171	0.34020
Within R^2	2.23×10^{-5}	0.00593	-0.31172	-0.03314	-0.08290	-0.29579	-0.82810	0.13128	-3.4184	-2.3134	0.20165
Dependent variable mean		73,575.9	73,575.9	27,451.4	10,269.8	2,816.0	4,671.3	2,592.6	1,007.3	1,578.8	0.51280
Wald (2nd stage)			21.324	2.7190	5.3445	18.100	46.266	40.186	87.345	37.384	11.797
Wald (1st stage), Hospice Entry			90.055	90.055	90.055	90.055	90.055	90.055	90.055	90.055	88.228

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table repeats instrumental variables estimates from equations (1) and (2) on mortality and spending outcomes, on a sample of patients who do not move after diagnosis with ADRD. The sample is smaller and the results are somewhat noisier, but qualitatively, the results are very similar to the main specification presented in Tables 3 and 4.

Table A4: Covariate Balance and Instrumental Validity

		Over 25mi (N=3759459)		Under 25mi (N=7095518)			
		Mean	Std. Dev.	Mean	Std. Dev.	Diff. in Means	Std. Error
Total Pmt		69494.97	71919.11	86898.23	89938.75	17403.26	50.16
Year of DX		2005.79	4.35	2006.96	4.33	1.17	0.00
Acute Myocardial Infarction		0.01	0.11	0.01	0.11	-0.00	0.00
Atrial Fibrillation		0.12	0.32	0.12	0.33	0.00	0.00
Cataracts		0.24	0.42	0.22	0.41	-0.02	0.00
Chronic Kidney Disease		0.12	0.33	0.15	0.36	0.03	0.00
COPD		0.15	0.36	0.15	0.36	-0.00	0.00
Heart Failure		0.26	0.44	0.27	0.44	0.01	0.00
Diabetes		0.26	0.44	0.28	0.45	0.03	0.00
Glaucoma		0.11	0.31	0.12	0.32	0.01	0.00
Hip Fracture		0.02	0.13	0.02	0.13	-0.00	0.00
Ischemic Heart Disease		0.38	0.48	0.40	0.49	0.03	0.00
Depression		0.16	0.37	0.17	0.37	0.01	0.00
Osteoperosis		0.08	0.28	0.09	0.29	0.01	0.00
Rheumatoid Arthritis		0.30	0.46	0.32	0.47	0.03	0.00
Stroke / Transiet Ischemic Attack		0.09	0.28	0.09	0.28	0.00	0.00
Breast Cancer		0.03	0.16	0.03	0.17	0.00	0.00
Colorectal Cancer		0.02	0.12	0.02	0.13	0.00	0.00
Prostate Cancer		0.04	0.19	0.04	0.19	0.00	0.00
Lung Cancer		0.01	0.09	0.01	0.10	0.00	0.00
Endometrial Cancer		0.00	0.05	0.00	0.05	0.00	0.00
Anemia		0.28	0.45	0.32	0.47	0.04	0.00
Asthma		0.04	0.19	0.04	0.21	0.01	0.00
Hyperlipidemia		0.30	0.46	0.35	0.48	0.05	0.00
Benign Prostatic Hyperplasia		0.06	0.23	0.06	0.24	0.01	0.00
Hypertension		0.56	0.50	0.61	0.49	0.04	0.00
Acquired Hypothyroidism		0.10	0.30	0.10	0.30	-0.00	0.00
		N	Pct.	N	Pct.		
Sex	Female	2296522	61.1	4399119	62.0		
	Male	1462937	38.9	2696399	38.0		
Age at DX	¡65	169109	4.5	334547	4.7		
	65-74	622411	16.6	1193735	16.8		
	75-84	1495476	39.8	2770540	39.0		
	85-94	1287203	34.2	2449697	34.5		
	95+	185260	4.9	346999	4.9		
Race	Black	238530	6.3	769966	10.9		
	Hispanic	45102	1.2	157965	2.2		
	Other	79554	2.1	236778	3.3		
	White	3396273	90.3	5930809	83.6		
ESRD	ESRD	43487	1.2	118661	1.7		
	Not ESRD	3715972	98.8	6976857	98.3		

Notes: This table tests instrumental validity using covariate values from the analytical sample, i.e., Medicare recipients diagnosed with ADRD between 2000 and 2014 who had not been to hospice before their diagnosis. The first two columns refer to Medicare recipients who, at the year before their diagnosis, were over 25 miles from the nearest for-profit hospice. The third and fourth column refer to Medicare recipients who, at the year before their diagnosis, were under 25 miles from the nearest for-profit hospice. The final two columns present differences in these two samples.

Table A5: Months of Life Lost

Dependent Variable:	Months of Life
Model:	(1)
Variables	
Hospice Entry	-9.738***
	(1.801)
Fixed-effects	
Demographics Controls	Yes
Chronic Conditions Controls	Yes
Zip Code	Yes
Diagnosis Cohort	Yes
Fit statistics	
Observations	10,856,191
R^2	0.21729
Within R^2	0.03465
Dependent variable mean	30.882
Wald (2nd stage)	29.219
Wald (1st stage), Hospice Entry	343.45

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table presents a regression that estimates the effect of hospice enrollment on months of life using distance to a for-profit hospice as an instrument, controlling for patient demographics and chronic conditions, as well as diagnosis cohort and zip code fixed effects. The regression is estimated at the patient level among a sample of Medicare beneficiaries diagnosed with ADRD between 2000 and 2014 who had not been to hospice in the years before their ADRD diagnosis. The dependent variable is defined by the months of life the patient has between one and five years after their ADRD diagnosis. It, therefore, ranges from 0 (i.e., the patient died in the year of her ADRD diagnosis) to 60 (i.e., the patient lived until at least 5 years after their ADRD diagnosis year).

Table A6: Predictability of Patient Stay Length

Dependent Variables:	Days to Death		Died Over 180D	
Model:	(1)	(2)	(3)	(4)
Fixed-effects				
Demographics Controls	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes
Diagnosis Cohort		Yes		Yes
Zip Code		Yes		Yes
Fit statistics				
Observations	6,772,839	6,772,839	6,772,839	6,772,839
R^2	0.01461	0.68851	0.00534	0.67611
Dependent variable mean	35.268	35.268	0.03644	0.03644

Notes: This table regresses a patient's days to death, or an indicator for living beyond 6 months, using information available to hospices at the time of hospice entry. The low R^2 value using demographics and chronic conditions highlights the uncertainty hospices face in estimating patient stay length.

Table A7. Descriptive Statistics on Hospice Anti-Fraud Lawsuits

	Value
Court Outcomes	
Dismissed	56%
Pending	7%
Settled	37%
Settlements	
Mean	$5.9 Mil
Median	$2.8 Mil
Total	$351 Mil
Top Judicial Districts (by Case Count)	
Missouri-West	14
Alabama-North	12
Georgia-North	11
Ohio-South	10
Florida-Middle	8
Top Judicial Districts (by Settlements)	
Missouri-West	$81 Mil
Wisconsin-East	$38 Mil
Alabama-North	$30 Mil
Texas-North	$18 Mil
Colorado	$18 Mil
Date Received (Year)	
Min	1998
Median	2013
Max	2021
Time from Date Received to Date Settled (Days)	
Min	28
25th Percentile	647
Median	1152
75th Percentile	1788
Max	3879

Notes: This table presents descriptive statistics from 163 federal False Claims Act anti-fraud lawsuits against hospice companies, using data from a Freedom of Information Act request we filed with the Department of Justice.

Table A8. IV Estimates for Hospice Effect on Spending and Mortality in Cancer Sample

Dependent Variables:	Hospice Entry	Total Pmt		Inpatient	Outpatient	Home Health	SNF	All Hospice	Forprofit Hospice	Nonprofit Hospice	Died w/in 5Y
Model:	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
Variables											
Forprofit Distance (10mi)	-0.0026***										
	(0.0003)										
Hospice Entry		13,141.8***	-83,057.7***	-12,982.4*	14,803.0**	-8,858.9***	-24,100.4***	11,923.3***	33,475.9***	-21,176.1***	0.2919***
		(92.67)	(17,986.3)	(7,873.2)	(6,403.2)	(2,082.3)	(3,543.2)	(1,880.9)	(3,581.9)	(3,463.4)	(0.0850)
Fixed-effects											
Demographics Controls	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chronic Conditions Controls	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zip Code	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Diagnosis Cohort	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fit statistics											
Estimate	OLS	OLS	IV	IV	IV	IV	IV	IV	IV	IV	IV
Observations	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,954,112	6,865,641
R^2	0.07682	0.14618	-0.12666	0.06827	0.06783	-0.17968	-0.66381	0.16170	-3.2817	-2.2171	0.34020
Within R^2	2.23×10^{-5}	0.00593	-0.31172	-0.03314	-0.08290	-0.29579	-0.82810	0.13128	-3.4184	-2.3134	0.20165
Dependent variable mean		73,575.9	73,575.9	27,451.4	10,269.8	2,816.0	4,671.3	2,592.6	1,007.3	1,578.8	0.51280
Wald (2nd stage)			21.324	2.7190	5.3445	18.100	46.266	40.186	87.345	37.384	11.797
Wald (1st stage), Hospice Entry			90.055	90.055	90.055	90.055	90.055	90.055	90.055	90.055	88.228

Clustered (Zip Code) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table presents spending and mortality estimates using the instrumental variables design described in equations (1) and (2) on patients with any form of cancer. Like Tables (3) and (4), we measure spending by category, and mortality over different periods, within 5 years of diagnosis. Hospice use is instrumented with distance to for-profit hospice, including zip-code and diagnosis cohort fixed effects.

Table A9: Targeting Effect of Lawsuits on Patient Characteristics

Dependent Variables:	Share with ADRD	Pre-Hospice Qntl1	Pre-Hospice Qntl2	Pre-Hospice Qntl3	Pre-Hospice Qntl4	Pre-Hospice Qntl5
Model:	(1)	(2)	(3)	(4)	(5)	(6)
Variables						
Firm Sued	-0.0138***	-0.0051***	-0.0044***	-0.0001	-0.0024**	-0.0018*
	(0.0027)	(0.0010)	(0.0009)	(0.0010)	(0.0009)	(0.0010)
Fixed-effects						
Hospice	Yes	Yes	Yes	Yes	Yes	Yes
Year	Yes	Yes	Yes	Yes	Yes	Yes
Fit statistics						
Observations	66,708	66,708	66,708	66,708	66,708	66,708
R^2	0.66756	0.35583	0.39885	0.38196	0.40103	0.50161
Within R^2	0.00097	0.00056	0.00046	2.34×10^{-7}	0.00010	7.26×10^{-5}
Dependent variable mean	0.34788	0.06982	0.06799	0.07052	0.07174	0.06780

Clustered (Hospice) standard-errors in parentheses
*Signif. Codes: ***: 0.01, **: 0.05, *: 0.1*

Notes: This table presents results from regressions each estimated using equation (5), a difference-in-difference specification that estimates firm-level responses to being sued. The regression is estimated at the hospice-year level. The dependent variables are the share of admissions with an ADRD diagnosis (Column 1), broken out by quintiles of pre-hospice spending among ADRD hospice patients.